Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 17/20 | 0.91 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.91 |
| ▸ | JAK3 | P52333 | 3/20 | 0.91 |
| ▸ | JAK1 | P23458 | 2/20 | 0.91 |
| ▸ | TYK2 | P29597 | 2/20 | 0.91 |
| ▸ | IKBKB | O14920 | 1/20 | 0.91 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.91 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.91 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.91 |
| ▸ | FYN | P06241 | 1/20 | 0.91 |
| ▸ | RET | P07949 | 1/20 | 0.91 |
| ▸ | HCK | P08631 | 1/20 | 0.91 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.91 |
| ▸ | PIM1 | P11309 | 1/20 | 0.91 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.91 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.91 |
| ▸ | PRKCA | P17252 | 1/20 | 0.91 |
| ▸ | PRKACA | P17612 | 1/20 | 0.91 |
| ▸ | FLT1 | P17948 | 1/20 | 0.91 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29521847 | 1.00 | JAK2 (0.91) | JAK2CHEK1JAK3JAK1TYK2 | |
| SCHEMBL1679794 | 0.95 | JAK2 (1.00) | JAK2CHEK1JAK3JAK1TYK2 | |
| SCHEMBL5761824 | 0.84 | JAK2 (0.66) | JAK2CHEK1JAK3JAK1TYK2 | |
| SCHEMBL5759495 | 0.84 | JAK2 (0.65) | JAK2CHEK1JAK3JAK1TYK2 | |
| SCHEMBL5759753 | 0.83 | JAK2 (0.68) | JAK2CHEK1JAK3JAK1TYK2 | |
| SCHEMBL2304822 | 0.83 | JAK2 (0.64) | JAK2CHEK1JAK3JAK1TYK2 | |
| SCHEMBL13741485 | 0.83 | JAK2 (0.71) | JAK2CHEK1JAK3JAK1TYK2 | |
| SCHEMBL3311115 | 0.83 | JAK2 (0.67) | JAK2CHEK1JAK3JAK1TYK2 | |
| SCHEMBL4099738 | 0.82 | JAK2 (0.63) | JAK2CHEK1JAK3JAK1TYK2 | |
| SCHEMBL8091367 | 0.81 | JAK2 (0.62) | JAK2CHEK1JAK3JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365429-B1 | PRODUCTION OF VIRUS-RECEPTIVE PLURIPOTENT STEM CELL (PSC)-DERIVED HEPATOCYTES | FUJIFILM CELLULAR DYNAMICS INC (US) | 2020-03-11 | — | — | EP | claimed |
| US-10093903-B2 | Production of virus-receptive pluripotent stem cell (PSC)-derived hepatocytes | FUJIFILM Cellular Dynamics, Inc. (US) | 2018-10-09 | — | — | US | claimed |
| EP-3365429-A1 | PRODUCTION OF VIRUS-RECEPTIVE PLURIPOTENT STEM CELL (PSC)-DERIVED HEPATOCYTES | FUJIFILM Cellular Dynamics, Inc. (US) | 2018-08-29 | — | — | EP | claimed |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | claimed |
| WO-2017070145-A1 | PRODUCTION OF VIRUS-RECEPTIVE PLURIPOTENT STEM CELL (PSC)-DERIVED HEPATOCYTES | CELLULAR DYNAMICS INTERNATIONAL, INC. (US) | 2017-04-27 | — | — | WO | claimed |
| US-20170107485-A1 | PRODUCTION OF VIRUS-RECEPTIVE PLURIPOTENT STEM CELL (PSC)-DERIVED HEPATOCYTES | FUJIFILM Cellular Dynamics, Inc. | 2017-04-20 | — | — | US | claimed |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2010-07-08 | — | — | US | claimed |
| EP-2114403-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | Bayer Healthcare, LLC (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | claimed |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-05 | — | — | US | disclosed |
| US-20240058482-A1 | USES OF LABELED HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2024-02-22 | — | — | US | disclosed |
| EP-3803402-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2023-03-21 | — | — | US | disclosed |
| US-11534464-B2 | Direct reprogramming of cells to cardiac myocyte fate | DUKE UNIVERSITY (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2008144011-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES | AVALON PHARMACEUTICALS (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080242594-A1 | Methods for Promoting Stem Cell Proliferation and Survival | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2008-10-02 | — | — | US | disclosed |
| WO-2007059155-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| EP-1414443-B1 | BENZIMIDAZO 4,5-f|ISOQUINOLINONE DERIVATIVES | MERCK & CO INC (US) | 2006-11-15 | — | — | EP | disclosed |
| US-6852727-B2 | Benzimisazo[4,5-f]isoquinolinone derivatives | MERCK & CO., INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040176601-A1 | Benzimisazo[4,5-f]isoquinolinone derivatives | MERCK SHARP & DOHME LLC | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176601-A1 | Benzimisazo[4,5-f]isoquinolinone derivatives | JAK1, JAK3, JAK2 | JAK2 3/4885CHEK1 1006/4885JAK3 2/4885 |
| US-20240058482-A1 | USES OF LABELED HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AA1 | JAK2 1605/4885CHEK1 1052/4885JAK3 3772/4885 |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | JAK2 1208/4885CHEK1 47/4885JAK3 912/4885 |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | JAK2 85/4885CHEK1 812/4885JAK3 819/4885 |
| US-11534464-B2 | Direct reprogramming of cells to cardiac myocyte fate | MYLK2, TNNI3, TNNT2 | JAK2 3559/4885CHEK1 4402/4885JAK3 3462/4885 |
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AA1 | JAK2 1605/4885CHEK1 1052/4885JAK3 3772/4885 |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | JAK2 1208/4885CHEK1 47/4885JAK3 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.